Companies /Healthcare

Akebia Therapeutics Inc

NASDAQ: AKBA Drug Manufacturers - Specialty & Generic
$0.47
▼ $0.02 (−4.78%) today
Markets open · 2:34pm ET

AKBA at a Glance

Valuation
Market cap
$131.7M
Profitability
Revenue (TTM)
$197.2M
Profit margin
-22.6%
EPS (TTM)
$-0.17
Price
52-week range
$0 – $2
Street target
$3.00

Headquartered in Waltham, MA Fiscal year ends December NASDAQ: AKBA akebia.com

About Akebia Therapeutics

Akebia Therapeutics is a fully integrated biopharmaceutical company focused on kidney disease. It has two commercial products.

- **Vafseo (vadadustat):** A once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months. It is approved in 37 countries and is in U.S. commercial launch, with about 11,500 active patients at the end of Q3 2026.
- **Auryxia (ferric citrate):** A legacy product whose revenues are declining due to generic competition and pricing pressure.

The company also earns license, collaboration, royalty and supply revenues.

Its clinical-stage rare kidney disease pipeline includes:
- **Ebribafusp alfa:** A potential next-generation complement inhibitor in a Phase 2 basket trial in C3 glomerulopathy, lupus nephritis and IgA nephropathy.
- **Praliciguat:** In Phase 2 development for focal segmental glomerulosclerosis (FSGS).

Akebia trades on Nasdaq under the ticker AKBA. Updated

AKBA Coverage

Frequently Asked Questions

What does Akebia Therapeutics do?

Akebia Therapeutics is a fully integrated biopharmaceutical company focused on kidney disease.

What is the AKBA stock price target?

The Wall Street consensus 12-month price target for AKBA is $3.00.